跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PD-1 checkpoint inhibitor (cancer)
首页
药物
PD-1 checkpoint inhibitor (cancer)
PD-1 checkpoint inhibitor (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2015
CN
EP
US
WO
10 件公开
COMPANION DIAGNOSIS BIOMARKER COMPOSITION AND COMPANION DIAGNOSIS KIT CONTAINING SAME
申请人: INNOBATION BIO CO LTD
优先权: 2020
CN
EP
2 件公开
INKT cell modulator liposome compositions and checkpoint inhibitor treatments
申请人: IOS THERAPEUTICS INC
优先权: 2023
CN
COMBINATION THERAPY FOR THE TREATMENT OF IMMUNE CHECKPOINT BLOCKADE RESISTANT CANCERS
申请人: WISCONSIN ALUMNI RES FOUND
优先权: 2026
US
Therapeutic agent for EGFR gene mutation positive lung cancer containing REIC/Dkk-3 gene
申请人: MOMOTARO GENE INC
优先权: 2020
CN
COMBINATION OF A KRAS G12C INHIBITOR WITH AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF CANCER
申请人: FRONTIER MEDICINES CORP
优先权: 2024
WO
Combination of immunomodulatory agent with PD-1-or PD-l1 checkpoint inhibitors in the treatment of cancer
申请人: HZNP LMITED
优先权: 2015
CN
Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer
申请人: SHANGHAI INST BIOLOGICAL SCIENCES CAS
优先权: 2016
US
药物
反馈